KD6001 is a humanized IgG1kappa monoclonal antibody targeting CTLA4. It effectively disrupts the interaction between CTLA-4 and CD80 (IC50: 16 ng/mL) as well as CD86. KD6001 enhances the expression of IL-2 and IFNgamma in PHA-activated human lymphocytes, demonstrating potent antitumor activity. It significantly inhibits tumor growth in mouse models with MC38, B16, and Hepa1-6 tumors. KD6001 is applicable in cancer research, including studies on advanced melanoma, hepatocellular carcinoma, and liver cancer.
CAS Number:
[2983061-18-1]
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted
